Saccharomyces boulardii in childhood

Vandenplas, Yvan; Brunser, O; Szajewska, Hania

doi:10.1007/s00431-008-0879-7

Cited by 63 publications

(17 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several published data focus on hospitalized patients. However, for some probiotics, such as S. boulardii , the vast majority of data are obtained in ambulatory care and in the developing world [ 10 ]. As a result of strain and product specificities (especially for products containing mixtures of probiotic strains) and to be in agreement with the recommendations of official and scientific organizations, it is recommended to perform randomized controlled trials with each commercialized product [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of the Probiotic Probiotical Confirmed in Acute Gastroenteritis

Kluijfhout

Trieu²,

Vandenplas

2020

Pediatr Gastroenterol Hepatol Nutr

Self Cite

View full text Add to dashboard Cite

Purpose: Some probiotic strains reduce the duration of acute diarrhea. Because of strain and product specificity, each product needs to be supported by clinical data. This study aimed to test the efficacy of the synbiotic food supplement Probiotical (Streptococcus thermophilus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium infantis, fructo-oligosaccharides) in children with acute gastroenteritis of likely infectious origin. The primary endpoint was the number of children with normal stool consistency during the treatment duration. Methods: A total of 46 children (aged 3.6 months to 12 years) with acute gastroenteritis that started less than 48 hours prior to their visit at a hospital-based emergency department were included in this prospective, randomized, placebo-controlled trial. All children were treated with oral rehydration solution and placebo (n=20) or the test product (n=26). Results: Significantly more children had a normal stool consistency on days 1 and 2 in the probiotic group: 5 children (20%) on day 1 in the probiotic group compared with none in the placebo group (p=0.046). On day 2, 11 children in the probiotic group (46%) and 3 (16%) in the placebo group (p=0.024) had a normal stool consistency. The mean duration of diarrhea was shorter in the probiotic group compared with that in the placebo group (3.04±1.36 vs. 4.20±1.34 days) (p=0.018). Conclusion: The test product was shown to normalize stool consistency significantly more rapidly than the placebo. These data confirm the findings from a previous study in a larger group of children performed in a primary healthcare setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of the Probiotic Probiotical Confirmed in Acute Gastroenteritis

Kluijfhout

Trieu²,

Vandenplas

2020

Pediatr Gastroenterol Hepatol Nutr

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies reported that the mechanisms of action of S. boulardii in the treatment of diarrhea could include the following 4 aspects: i) effects of anti-bacterial toxins; ii) direct or indirect inhibition of growth of intestinal pathogens, such as Candida albicans , Salmonella , Yersinia ; iii) increase of short chain fatty acids concentrations; iv) immunomodulatory effects such as an increase in sIgA [ 13 ]. H. pylori interacts with the host immune response by upregulation of various cytokines, such as tumor necrosis factor-α, interferon-γ, interleukin (IL)-1, IL-6 and IL-8 [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

The Efficacy ofSaccharomyces boulardiiCNCM I-745 in Addition to StandardHelicobacter pyloriEradication Treatment in Children

Zhang

Deng

et al. 2015

Pediatr Gastroenterol Hepatol Nutr

Self Cite

View full text Add to dashboard Cite

PurposeThis study aims to investigate Saccharomyces boulardii CNCM I-745 during Helicobacter pylori eradication in children.MethodsOne hundred ninety-four H. pylori positive children were randomized in two groups. Therapy (omeprazole+clarithromycin+amoxicillin or omeprazole+clarithromycin+metronidazole in case of penicillin allergy) was given to both groups during two weeks. In the treatment group (n: 102) S. boulardii was added to the triple therapy, while the control group (n: 92) only received triple therapy. The incidence, onset, duration and severity of diarrhea and compliance to the eradication treatment were compared. A 13C urea breath test was done 4 weeks after the end of eradication therapy in two groups of 21 patients aged 12 years and older to test the H. pylori eradication rate.ResultsIn the treatment group, diarrhea occurred in 12 cases (11.76%), starting after 6.25±1.24 days, lasting 3.17±1.08 days, and compliance to eradication treatment was 100%. In the control group, diarrhea occurred in 26 cases (28.26%), starting after 4.05±1.11 days, lasting 4.02±0.87 days, and in six cases eradication treatment was stopped prematurely (p<0.05). The 13C urea breath test showed successful H. pylori eradication in 71.4% of the patients in the treatment and in 61.9 % in the control group (not significant).ConclusionS. boulardii has a beneficial effect on the prevention and treatment of diarrhea during H. pylori eradication in children. Although S. boulardii did only slightly increase H. pylori eradication rate, compliance to eradication treatment was improved.

show abstract

“…It was reported that S. boulardii had improved the post-treatment dyspepsia symptoms of H. pyloris infection without having a significant effect on the rate of H. pylori eradication (Cindoruk et al, 2007). Recently, Vandenplas et al (2009) suggested that S. boulardii alters the structure of H. pylori . Further studies are required for better understanding of yeast probiotics mechanisms.…”

Section: Applications Of Antagonistic Activities Of Yeastsmentioning

confidence: 99%

Antimicrobial and Probiotic Properties of Yeasts: From Fundamental to Novel Applications

Labrie²,

2012

View full text Add to dashboard Cite

The yeasts constitute a large and heterogeneous group of microorganisms that are currently attracting increased attention from scientists and industry. Numerous and diverse biological activities make them promising candidates for a wide range of applications not limited to the food sector. In addition to their major contribution to flavor development in fermented foods, their antagonistic activities toward undesirable bacteria, and fungi are now widely known. These activities are associated with their competitiveness for nutrients, acidification of their growth medium, their tolerance of high concentrations of ethanol, and release of antimicrobial compounds such as antifungal killer toxins or “mycocins” and antibacterial compounds. While the design of foods containing probiotics (microorganisms that confer health benefits) has focused primarily on Lactobacillus and Bifidobacterium, the yeast Saccharomyces cerevisiae var. boulardii has long been known effective for treating gastroenteritis. In this review, the antimicrobial activities of yeasts are examined. Mechanisms underlying this antagonistic activity as well as recent applications of these biologically active yeasts in both the medical and veterinary sectors are described.

show abstract

Saccharomyces boulardii in childhood

Cited by 63 publications

References 81 publications

Efficacy of the Probiotic Probiotical Confirmed in Acute Gastroenteritis

Efficacy of the Probiotic Probiotical Confirmed in Acute Gastroenteritis

The Efficacy ofSaccharomyces boulardiiCNCM I-745 in Addition to StandardHelicobacter pyloriEradication Treatment in Children

Antimicrobial and Probiotic Properties of Yeasts: From Fundamental to Novel Applications

Contact Info

Product

Resources

About